Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Candi5V
- Development stage
- Phase 2
- Lead developer
- LimmaTech Biologics
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Candi5V is a pentavalent bioconjugate vaccine developed as an immunostimulant for the prevention of Candida infections. As a vaccine, it is designed to stimulate an immune response against multiple (five) distinct antigens from the Candida genus, addressing the unmet need for a broad-coverage prophylactic against various types of candidiasis. This formulation is intended to prevent invasive and mucosal Candida infections, which are significant concerns especially in immunocompromised populations. Development is led by LimmaTech Biologics AG.
- Brand names
- Candi5VCandi-5VCandi 5V
- Other names
- Candi5VCandi-5VCandi 5V
02
Targets
Mannan
Beyond the preview
Go deeper on Candi5V.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Candi5V.